NASDAQ:GCTK GlucoTrack Q2 2025 Earnings Report $0.36 +0.00 (+0.14%) Closing price 06/23/2026 04:00 PM EasternExtended Trading$0.36 0.00 (-0.93%) As of 06/23/2026 07:58 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. ProfileEarnings HistoryForecast GlucoTrack EPS ResultsActual EPS-$9.62Consensus EPS N/ABeat/MissN/AOne Year Ago EPSN/AGlucoTrack Revenue ResultsActual RevenueN/AExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/AGlucoTrack Announcement DetailsQuarterQ2 2025Date8/14/2025TimeAfter Market ClosesConference Call DateThursday, August 14, 2025Conference Call Time7:00AM ETConference Call ResourcesPress Release (8-K)Quarterly Report (10-Q)Earnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(8-K)Quarterly report(10-Q) GlucoTrack Earnings HeadlinesGlucotrack to Highlight Implantable Continuous Blood Glucose Monitoring Technology at the American Diabetes Association’s 2026 Scientific SessionsMay 26, 2026 | markets.businessinsider.comGlucotrack to Highlight Implantable Continuous Blood Glucose Monitoring Technology at the American Diabetes Association's 2026 Scientific SessionsMay 26, 2026 | globenewswire.comNow that SpaceX is public, buy this ticker (no, not SpaceX or Tesla)The SpaceX IPO wasn't the big trade - according to Larry Benedict, founder of The Opportunistic Trader, it was the trigger. Benedict, who delivered a 279% return on cash in 2025 across a 20-year winning streak, says the listing launched what he calls the 'Final Phase of Elon's Master Plan.' He's identified one specific ticker - not SpaceX, Tesla, or any Elon-affiliated company - that he believes could see billions in inflows as this phase unfolds. He calls it his trade of the year. | Brownstone Research (Ad)GlucoTrack, Inc.: Glucotrack Reports First Quarter 2026 Financial Results and Recent Corporate HighlightsMay 15, 2026 | finanznachrichten.deGlucotrack Reports First Quarter 2026 Financial Results and Recent Corporate HighlightsMay 14, 2026 | globenewswire.comGlucoTrack Inc.May 13, 2026 | marketwatch.comSee More GlucoTrack Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like GlucoTrack? Sign up for Earnings360's daily newsletter to receive timely earnings updates on GlucoTrack and other key companies, straight to your email. Email Address About GlucoTrackGlucoTrack (NASDAQ:GCTK), a medical device company, focused on the design, development, and commercialization of novel technologies for people with diabetes in the United States. It develops GlucoTrack, a noninvasive glucose monitoring device that helps people with diabetes and pre-diabetics to obtain blood glucose level readings without the pain. The company was formerly known as Integrity Applications, Inc. and changed its name to GlucoTrack, Inc. in November 2021. GlucoTrack, Inc. was founded in 2001 and is based in Rutherford, New Jersey.View GlucoTrack ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Micron’s Sudden Plunge May Be an AI Buying ChanceLiquid Gold: The AI Cooling Retrofit TradeCopa Holdings May Be the Airline Stock Built to Break OutBuy CrowdStrike Before the Stock Split? Here's the CaseUSA Today's Digital Revival Is Gaining Steam, But With Plenty of RiskBurlington Is Winning Over Shoppers But Investors Need PatienceInvestors Are Buying Into Sweetgreen Again—Should They? Upcoming Earnings Micron Technology (6/24/2026)NIKE (6/30/2026)PepsiCo (7/9/2026)Delta Air Lines (7/9/2026)Fastenal (7/13/2026)Bank of America (7/14/2026)The Goldman Sachs Group (7/14/2026)JPMorgan Chase & Co. (7/14/2026)Wells Fargo & Company (7/14/2026)Citigroup (7/14/2026) Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
